PARIS & LEIDEN, the Netherlands – Iktos, a company specialized in Artificial Intelligence for new drug design, and Facio Therapies, a drug discovery and development company focused on developing treatments for facioscapulohumeral dystrophy (FSHD), today announced entering a collaboration to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of...
Latest News
DORVAL, QC – Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris® (canakinumab) for the treatment of active Still’s disease, including adult-onset Still’s disease (AOSD)[1]. AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications[2]....
The midfielder is auctioning off his signed match-worn shirt from Manchester City’s 2-1 win over Borussia Dortmund in the first leg of our Champions League quarter-final, with all proceeds being used to help fund Dilara Abanoglu’s life-saving surgery. Dilara was diagnosed with Ollier’s Disease – a skeletal disorder which affects...
San Diego — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, begins a monthlong celebration of its 25th anniversary. A quarter-century after its founding in San Diego in April 1998, the company is commemorating its anniversary by celebrating its employees, customers, and entire stakeholder ecosystem,...
HORSHAM, Pa. — Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension (OLE) in a broad population of antibody-positive (including anti-AChR+a and anti-MuSK+b) adults with generalized myasthenia gravis (gMG) reinforcing the efficacy, sustained disease control and proven safety profile of IMAAVY® (nipocalimab-aahu)....
Birmingham, UK – Pathological abnormalities associated with motor neurone disease have been identified using a new technique developed at the University of Birmingham. The method will help scientists better understand the changes in the brain that lead to motor neurone disease (MND) and could eventually yield insights that will help...
BEERSE, Belgium – The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study (PCYC-1142), showing 95 percent of patients treated with fixed duration combined IMBRUVICA® (ibrutinib) plus venetoclax were alive and progression-free at two years [1]. Deep remissions...
Marseille, France – ImCheck Therapeutics today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A) monoclonal antibody designed to selectively activate γ9δ2 T cells, for the treatment of acute myeloid leukemia (AML). The designation in the...
Marseille, France – ImCheck Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A) monoclonal antibody designed to selectively activate γ9δ2 T cells, for the treatment of acute myeloid leukemia (AML). AML remains a significant clinical...
POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). Positive high-level results from the final analysis of POSEIDON showed the combination of Imfinzi, tremelimumab and chemotherapy demonstrated...